Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

WASHINGTON (7News) — Daiichi Sankyo Inc., an innovative pharmaceutical company deep with ties to the Cherry Blossoms in Washington, DC dates back more than a century to the company's first president, ...

Daiichi Sankyo Co. said on Friday it submitted its mRNA-based COVID-19 vaccine for regulatory approval in Japan. Approval would give Japan a home-grown mRNA vaccine of the type that have made up ...

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) today and set a price target of ...

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Tuesday said Datroway has secured EU approval to treat breast cancer patients. Daiichi Sankyo, a Tokyo-based pharmaceutical company, and ...